Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice

INTRODUCTION: Romiplostim has been approved in Europe since 2009 to treat patients with chronic primary immune thrombocytopenia (ITP). Using real-world data from seven European countries, we measured the effectiveness and safety outcomes within 24 weeks following romiplostim initiation by duration o...

Descripción completa

Detalles Bibliográficos
Autores principales: Snell Taylor, Sara J., Nielson, Carrie M., Breskin, Alexander, Saul, Bradley, Yu, Ying, Alam, Naufil, Eisen, Melissa, Hippenmeyer, Jane, Janssens, Ann, Kozak, Tomas, Papadaki, Helen A., Selleslag, Dominik, Viallard, Jean-Francois, Feistritzer, Clemens, Kaiafa, Georgia, Kelsh, Michael, Kilpatrick, Karynsa, Brookhart, M. Alan, McGrath, Leah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107157/
https://www.ncbi.nlm.nih.gov/pubmed/33866516
http://dx.doi.org/10.1007/s12325-021-01727-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107157/
https://www.ncbi.nlm.nih.gov/pubmed/33866516
http://dx.doi.org/10.1007/s12325-021-01727-5

Ejemplares similares